Q-omics provides the consensus-scored CIBAR2 profile across patient tissues and cancer cell-line models. CIBAR2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CIBAR2 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, CIBAR2 protein abundance shows 29,821 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, LUSC, and GBM as cancer lineages where CIBAR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CIBAR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CIBAR2 survival associations across molecular data types. CIBAR2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CIBAR2 RNA expression–survival associations across cancer types. High CIBAR2 expression shows unfavorable associations in KIRC, KIRP and ACC, but favorable associations in SKCM, HNSC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CIBAR2 RNA expression.
This table summarizes CIBAR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 5. The strongest signals are observed in LUSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CIBAR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CIBAR2 shows lower tumor expression in LUSC, LUAD, READ and CHOL and higher tumor expression in BRCA. The LUSC box plot shows higher CIBAR2 RNA expression in normal versus tumor tissue (log2 FC = −2.830, t-test p < 0.001).
This table shows molecular features associated with CIBAR2 in patient tissues and cancer cell lines. In patient samples, CIBAR2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CIBAR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
